Objectives: To determine the short-term tolerance, efficacy, and lung deposition of supraglottic atomized surfactant in spontaneously breathing lambs receiving continuous positive airway pressure. Design: Prospective, randomized animal study. Setting: Animal research laboratory. Subjects: Twenty-two preterm lambs on continuous positive airway pressure (132 ± 1 d gestational age). Interventions: Animals receiving continuous positive airway pressure via binasal prongs at 8 cm H 2 O were randomized to receive atomized surfactant at approximately 60-minute of life (atom; n = 15) or not (control; n = 7). The atom group received 200 mg/kg of poractant alfa (Curosurf; Chiesi Farmaceutici SpA, Parma, Italy) over 45 minutes via a novel atomizer located in the upper pharynx that synchronized surfactant delivery with the inspiratory phase. Measurements and Main Results: Arterial blood gas, regional distribution of tidal ventilation (electrical impedance tomography), and carotid blood flow were recorded every 15 minutes until 90 minutes after stabilizing on continuous positive airway pressure. Gas exchange, respiratory rate, and hemodynamic variables, including carotid blood flow, remained stable during surfactant treatment. There was a significant improvement in arterial alveolar ratio after surfactant delivery in the atom group (p < 0.05; Sidak posttests), while there was no difference in Paco 2 . Electrical impedance tomography data showed a more uniform pattern of ventilation in the atom group. In the atom group, the median (interquartile range) deposition of surfactant in the lung was 32% (22-43%) of the delivered dose, with an even distribution between the right and the left lungs. Conclusions: In our model of spontaneously breathing lambs receiving CPAP, supraglottic atomization of Curosurf via a novel device was safe, improved oxygenation and ventilation homogeneity compared with CPAP only, and provided a relatively large lung deposition suggesting clinical utility. (Pediatr Crit Care Med 2017; 18:e428-e434) 
S urfactant replacement is a very effective therapy for respiratory distress syndrome (RDS) and has significantly reduced the mortality and morbidity in preterm neonates (1) . The currently approved administration method consists of endotracheal intubation followed by intratracheal surfactant instillation, exposing infants to laryngoscopy and intubation. As identified in the CURPAP trial (2) , about one third of infants intubated for surfactant administration can be successfully extubated to continuous positive airway pressure (CPAP), suggesting that in these infants, intubation could be avoided if an alternative method for surfactant delivery is available.
Recently, new methods of delivering surfactant avoiding endotracheal intubation have been considered (3, 4) , but these require high technical skills and are still invasive, as the majority require introducing an administering catheter into the trachea. Although the treatment of neonates with nebulized surfactant would offer an attractive noninvasive alternative, it is still challenging (5) , and previous studies have reported inconsistent clinical response and surfactant distribution (6) (7) (8) (9) (10) (11) (12) (13) , likely due to the use of nebulizers not specifically designed for surfactant.
In experimental models, intracorporeal endotracheal surfactant atomization has proved to be effective (5, (14) (15) (16) , likely because it improves lung deposition bypassing the upper airways. Recently, we developed a novel system that allows atomization of surfactant anterior to the vocal chords without the need of intubation or visualizing the larynx, offering potential to administer surfactant during CPAP with less invasive handling (17) . This system consists of a small multilumen catheter, placed in the supraglottic region through a special airways management device (18) , that atomizes surfactant directly into the pharynx bypassing the nose. This device also synchronizes surfactant delivery to inspiration, detected from the intrapharyngeal pressure swings. In a previous proof of concept study in mechanically ventilated preterm lambs, surfactant delivered by the atomizing system via endotracheal tube (ETT) resulted in similar short-term benefits as bolus administration (19) .
The aims of the present study were to evaluate short-term tolerance, efficacy, and surfactant deposition within the lung of our atomization system in spontaneously breathing preterm lambs receiving CPAP. The primary outcomes were gas exchange, regional distribution of ventilation, and regional deposition of surfactant.
MATERIALS AND METHODS
A detailed description of the methods is found in the online supplement (Supplemental Digital Content 1, http://links. lww.com/PCC/A490). The study was performed at the Murdoch Childrens Research Institute (Melbourne, VIC, Australia) and approved by the Animal Ethics committee in accordance with the National Health and Medical Research Committee (Australia) guidelines.
Animal Preparation
Twenty-two Border-Leicester/Suffolk lambs were studied at 132 ± 1 days gestation (term~145 d). Lambs were delivered by caesarean section with maternal general anesthesia. Ewes were treated with betamethasone 11.4 mg intramuscular injection, 24 and 48 hours before the study day.
All lambs were instrumented while on placental support using our previously detailed methods (20) (21) (22) . A flow probe was placed into the carotid artery (TS420-Perivascular Flow Module; Transonic Systems, Ithaca, NY) to measure carotid blood flow (CBF). The fetus was then intubated, fetal lung fluid was drained passively. Following observations in our pilot studies (23) , an oesophageal balloon was placed to prevent stomach insufflation during CPAP which, in lambs, can lead to life-threatening thoracic compression. A custombuilt CPAP delivery interface made of binasal prongs was inserted, and the snout secured to reduce leaks during CPAP administration. Prior to this, the atomizing interface was inserted into the animals allocated to the atom group and correct position confirmed using flexible direct laryngoscopy. The interface was marked for subsequent placement after birth and removed. Sixteen custom-built electrical impedance tomography (EIT) electrodes were placed equidistant around the fetal chest in all animals using our previously described methodology (21, 22) and connected to a Goe-MF II EIT system (CareFusion, Hoechberg, Germany). A 10-second baseline recording of the unaerated lung was made as a reference.
Postnatal Lamb Management and Ventilation Strategy
After cord clamping, lambs were placed in prone position under a warmer. They received a 30-second sustained inflation at 30 cm H 2 O through the ETT to establish a functional residual capacity, followed by loading doses of caffeine (20 mg/kg) and doxapram (5 mg/kg). The ETT was then removed, and lambs were supported by noninvasive intermittent positive pressure ventilation (NIPPV) using 8 cm H 2 O positive end-expiratory pressure, 30 cm H 2 O peak inspiratory pressure (PIP), 0.4 seconds inspiratory time at 30 breaths/min, with the aim of weaning the lamb to CPAP within 45 minutes of life once regular effective breathing was established. Fio 2 was titrated to maintain peripheral oxygen saturation (Spo 2 ) between 90% and 96%. After 15 minutes of stable CPAP, the allocated study phase was commenced (defined as time zero [t0]). Ketamine (0.1-0.5 mg/kg IV) was administered as needed for any apparent discomfort. In all lambs, a suction catheter remained in situ within the oropharynx for intermittent gentle suction as clinically indicated of any accumulated saliva due to impaired swallow from the oesophageal balloon, and surfactant deposited in the upper airways (for the atom group).
Study Design
Prior to birth, animals were randomized to the following group:
Control Group (n = 7). Received no sham surfactant administration or had the interface and atomizing catheter in situ. Parma, Italy) marked using the samarium oxide (Sm 2 o 3 ) technique (24) during CPAP. At t0 + 10 minutes, the premarked interface and atomizing catheter were inserted and atomization commenced at t0 + 15 minutes. During atomization (45-75 min), CPAP was increased to 10 cm H 2 O, and Fio 2 increased by 0.1 to compensate for the additional respiratory resistance arising from the presence of the catheter interface and the dilution of administered oxygen due to the atomizing flow of air. At the end of surfactant delivery, the atomizing catheter and interface were removed, and the animal managed as per CPAP group.
All lambs were studied for t0 + 90 minutes. At the end of the study, lambs were sedated, intubated, and placed on intermittent positive pressure ventilation. Finally, they were humanely euthanized with a lethal dose of pentabarbitone and exposed to atmosphere for 2 minutes to deflate the lung to functional residual capacity. A pressure-volume curve was performed using a calibrated glass super syringe from 0 to 40 cm H 2 O to allow calibration of EIT (25) .
Measurements and Experimental Set-up
Spo 2 , Fio 2 , heart rate (HR), arterial blood pressure (HP48S monitor; Hewlett Packard, Andover, MA), CBF, and airway pressure (Florian, Acutronic Medical Systems, Hirzel, Switzerland) were recorded continuously from birth. All signals were sampled at 200 Hz and acquired using a Powerlab/LabChart system (Version 7; AD Instruments, Sydney, Australia). Arterial blood gas analyses were performed at 15 minutes of life and every 15 minutes from t0.
Atomized surfactant was delivered using our custom-built system (17, 26) . Briefly, the system was composed of an atomizing catheter connected to a device for delivery of surfactant during inspiration, triggered by the intrapharyngeal pressure measured by means of a thin (outer diameter 1 mm) sensing catheter placed in the pharynx. Atomizing catheters had a central lumen, in which the surfactant flowed (1.2 mL/min), and four outer lumens to deliver atomizing gas (compressed air) at flow 1.5 L/min. At the tip of the catheter, compressed air breaks the liquid jet producing particles with median diameter of 40-60 µm. Particle size was measured by laser diffraction method (Spraytech, Malvern Instruments, Malvern, United Kingdom). The pressure sensing catheter also allowed monitoring of pharyngeal pressure during the entire atomization procedure. This identified that the presence of the atomizing gas lead to a negligible increment in pharyngeal pressure; mean (sd) 0.05 (0.47) cm H 2 O.
An ad hoc interface (18) was placed in the oropharynx of lambs randomized to the atom group to keep the atomizing catheter in place and directed toward the inlet of the trachea. The interface was designed so that nasal breathing was not inhibited.
Data Analysis
Arterial alveolar (aA) ratio was determined at each arterial blood gas. Respiratory rate (RR), HR, and mean arterial pressure (MAP) were averaged over 30 seconds of artefact-free recordings. The mean CBF during each time period was determined from the CBF waveform. The EIT data were reconstructed using a custom-built EIT analysis program to generate functional EIT scans of the distribution of tidal ventilation during the 30-second period (25) . The pattern of fractional ventilation was determined within the lung regions at t0, 60, and 90 minutes.
Surfactant Deposition Study
For determination of pulmonary deposition, the surfactant was labeled with Sm 2 o 3 , a nonradioactive tracer, at a concentration of 0.33 mg Sm 2 o 3 per 3 mL Curosurf. To yield a homogenous suspension, Sm 2 o 3 nanoparticles were ultrasonically mixed vigorously with the surfactant shortly prior to nebulization. Pretesting showed no measurable segregation until nebulization. Spraying this suspension results in surfactant droplets evenly labeled with Sm 2 o 3 nanoparticles. Analytical characterization was performed by inductively coupled plasma mass spectrometry (ICP-MS) by the Fraunhofer Institute for Toxicology and Experimental Medicine (Fh-ITEM), Germany. Organic samples were processed prior to analysis by freeze-drying, reducing to ashes and digesting with a combination of hydrochloric acid, nitric acid, and water (27) .
Two pilot lambs receiving surfactant (200 mg/kg) via the INtubation-SURfactant-Extubation (INSURE) technique (28) were used as a reference for surfactant deposition. In their lung, the percentage of retrieved surfactant was 71% and 73%. Animals were transiently intubated 15 minutes after t0, and surfactant administered via a closed delivery system during positive pressure ventilation (PIP 40 cm H 2 O, rate 30-40 beats/ min). The animals were then extubated immediately to CPAP and managed as per the CPAP only group.
After euthanasia, the lungs and trachea were removed intact from the thorax for the atom and INSURE groups, weighed, inflated (30 cm H 2 O for 15 s, then 15 cm H 2 O for 15-30 s), and fixed in liquid nitrogen. The frozen lung tissues were then processed and analyzed by ICP-MS at Fh-ITEM to retrieve the concentration of Sm 2 o 3 in each lobe and in the trachea (29) .
Statistical Analysis
All data were tested for normality and analyzed with two-way analysis of variance (ANOVA) (using group and time as factors) and Bonferroni post hoc test. Statistical analysis was performed with GraphPad Prism 5.0. A p value of less than 0.05 being considered statistically significant. Table 1 summarizes the baseline characteristics of the two groups. There were no statistically significant differences between groups in terms of gestational age, body weight, cord pH, Paco 2 , Pao 2 , and Fio 2 after 15 minutes of NIPPV, before the beginning of the study phase. All the animals were able to complete the experiments without adverse events, in particular, no air leaks or hemodynamic impairments occurred.
RESULTS
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www.pccmjournal.org e431 Short-term Tolerance Figure 1 shows the relevant respiratory and circulatory parameters used to assess tolerance of the device and atomization process. The aA ratio was significantly higher in the control than in the atom group at t0 (two-way ANOVA, p < 0.001). However, no differences between groups were observed during the atomization. Although Paco 2 and RR were higher in the atom group from t0, the differences were not significant (p = 0.28 and p = 0.13, respectively). No differences in hemodynamic parameters were observed between groups (p = 0.54 and p = 0.47 for MAP and HR). All hemodynamic parameters, including mean CBF, remained substantially stable throughout the atomization period, with a slight reduction of CBF and MAP over time observed in both groups (Figs. 1, D The distribution of ventilation remained stable and relatively homogenous from t0 to t0 + 90 minutes (Fig. 3) . In contrast, the CPAP group showed more unstable ventilation patterns.
−F).
Efficacy
Deposition
In the atom group, the median (interquartile range [IQR]) recovery of surfactant in the lung was 32% (22-43%) of the delivered dose. Most of the recovered surfactant was found in the lung and only a small amount, median (IQR) 5.8% (5.0%), remained in the trachea. Overall, we observed an even distribution of Sm 2 o 3 between the right and the left lungs and a slightly higher, although nonsignificantly (p = 0.12, Wilcoxon matched-pair signed-rank test), deposition in the upper lobes (Fig. 4) ; median (IQR) deposition of 51.5% (12.14) in the upper lobe versus 38.2& (26.4) in the lower lobes. 
DISCUSSION
In our lamb model of spontaneously breathing preterm lamb receiving CPAP (23), surfactant atomization via a novel device allowing delivery above the vocal cords was well tolerated, produced a significant increase in oxygenation versus baseline and a stable and more homogeneous distribution of ventilation compared with CPAP alone. In addition, our system of administration showed a relatively homogenous deposition of Sm 2 o 3 into the lung. Most studies evaluating the efficacy of nebulized surfactant investigated delivery by extracorporeal devices placed within the ventilator circuit, with inconsistent clinical response and poor surfactant distribution (6, 10, 12, 13, 30, 31, 35) . Recently better outcomes compared with mechanical ventilation alone have been shown using intracorporeal atomization of surfactant (19) . In particular, lambs receiving intracorporeal atomization achieved high deposition rates (approximately 86.5%) (16) and showed an equivalent improvement in gas exchange, lung mechanics (14, 16, 19) , and regional distribution of ventilation (19) as bolus instillation. Atomization did demonstrate better surfactant distribution and less cerebral hemodynamic fluctuations than bolus instillation (15) , advocating atomization as a feasible method of delivery at least if surfactant is associated with mechanical ventilation and intubation.
Although the increasing use of noninvasive respiratory support is limiting the administration of surfactant to patients with mild to moderate RDS for whom it could still be beneficial (3, 4) . To date, no study has investigated supraglottic intracorporeal atomization during spontaneous breathing. Supraglottic delivery is challenging since the anatomy of the retropharyngeal region has evolved to protect the inlet of trachea from unknown bodies. Our solution, that slightly modified our previous device (19) , consisted of an ad hoc oropharyngeal airway management device. Such device kept the atomizing catheter in place, maintained the catheter away from the walls of the pharynx, directed toward the larynx, and minimized the likelihood of particles impacting the laryngeal walls before entering the trachea. This device was well tolerated in our lambs without additional sedation.
Co 2 clearance, RR, and hemodynamic parameters were not modified as atomization was started and remained stable throughout the treatment, indicating that the device and the administration procedure were safe. The stability of hemodynamic parameters are consistent with previous findings suggesting that aerosolized surfactant may partly avoid the hemodynamic fluctuations associated with bolus instillation (9, 15) .
In the atom group, oxygenation gradually improved after surfactant administration, rather than rapidly as reported after bolus surfactant (19) . This is explained by the fact that surfactant deposition is likely to take longer to reach unstable alveolar regions after atomization due to a number of mechanisms, including how big particles (40-60 mm) are distributed, diffusion gradients in the lung, the spreading properties of surfactant, the Marangoni effect, and capillarity. Co 2 remained stable in both groups. The lack of improvement in the atom group could be due to the fact that lambs were within the physiologic range prior to receiving surfactant (32) .
The two groups had significantly different oxygenation at baseline with the control group, thus, having less capacity for improvement. The more even distribution of ventilation throughout the study in the atom group, and a more uniform pattern of ventilation at study completion compared with CPAP alone, suggests that the improvements in oxygenation reflected efficacy of the surfactant treatment and supporting deep lung delivery.
Compared with previous studies (10%), a relatively high amount of Sm 2 o 3 (33%), and by induction, atomized surfactant reached the lung (6, 10, 13, 29, 31 ). We hypothesized that this high recovery rate was due to the combination of placement of the tip of the catheter at the inlet of the trachea, the use of large particles (33) , and the synchronization with inspiration. Sm 2 o 3 was deposited in all lung lobes suggesting, along with the uniform ventilation, that atomized surfactant was also. Sm 2 o 3 was higher, although nonsignificantly, in the upper lobes, in agreement with previous studies (30, 34) . The use of an oesophageal balloon to prevent stomach inflation prevented surfactant deposition into the stomach. However, in our opinion, this did not alter lung deposition, since it is very likely that the surfactant not entering the trachea accumulated in the pharynx and was removed by the frequent suctions performed to remove secretions.
We advocate that this methodology could be translated to humans in the near future. In our opinion, species-specific design of the interface would allow autopositioning of the interface, avoiding the use of the direct visual inspection that in this study was used only for confirmation. If self-positioning is fulfilled, this methodology has the potentiality to become less invasive than other (3, 4) alternatives to bolus instillation, since it does not require the passage of any device through the vocal cords or the use of a laryngoscope.
Although we tried to limit differences in lung immaturity and standardized the gestational age, we observed great variability in the severity of RDS among animals. Specifically, the control group had better oxygenation at t0, probably due to the imbalance in the sample size among groups. Even though the two groups did not differ in terms of cord blood gas at birth, the difference observed once the animals were weaned off nasal ventilation cannot be associated with the treatment of the atom group as up to that point, the protocol was exactly the same for both groups. Human infants demonstrate significant differences in upper airway anatomy, fetal fluid levels, central control of pharyngeal tone, and breathing pattern compared with lambs, therefore, translating our results to humans requires caution. Nevertheless, the more complicated upper airways management, greater secretions, and high rates of apnea in lambs explain why our study is one of the first to report noninvasive respiratory support in a highly instrumented lamb model. The airway management device used in the present study, being a customized prototype device for lambs, was not optimized in terms of shape and materials. This limitation may be responsible for both the increased production of viscous secretions observed in the atom group and for the variability in deposition. To compensate for the additional respiratory load due to the presence of interface, we increased the CPAP in the atom group by 2 cm H 2 O only during the period in which the interface was in place (surfactant administration). This may have resulted in higher pressure being applied to the atom group and, therefore, contributed to the differences observed between groups.
CONCLUSIONS
In our preterm lamb model of early moderate RDS during stable breathing on CPAP, supraglottic delivery of surfactant via a novel atomizer system was well tolerated. Compared with CPAP only, distribution of ventilation was more homogeneous and oxygenation improved following surfactant delivery. This suggests that atomization of surfactant in spontaneously breathing lamb model receiving noninvasive respiratory support is feasible and may result in clinically relevant deposition into the deep lung. The encouraging results of this study justify further development of this technique in order to make it suitable for the application to humans.
